Genospace LLC, Cambridge, Mass, will merge with Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), Nashville, Tenn, and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace seek to harness molecular profiling data to match cancer patients with cutting-edge therapies in clinical trials.
Genospace, which will remain based in Cambridge, is leading the development and enhancement of a cloud-based system that enables analysis of disparate data from clinical and laboratory sources across patient populations.
Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, Hospital Corporation of America.
“Genospace’s innovative technology approach to understanding each patient’s cancer directly supports our strategic goal of personalizing care delivery,” says Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, president of clinical services and chief medical officer at HCA. “By tailoring treatments based on the unique genetic make-up of a patient’s cancer, we can more effectively treat the disease.”
Through the collaboration of Sarah Cannon and Genospace, the genomics data technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.
Howard A. “Skip” Burris III, MD, Sarah Cannon.
“As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making,” says Howard A. “Skip” Burris III, MD, president of clinical operations and chief medical officer at Sarah Cannon. “Genospace’s leadership in this field will help us to transform the way we gather and analyze genomic information, resulting in better identification of effective treatment options for our patients.”
The company’s platform also provides patient-facing portals and disease-specific communities to support and educate patients across disease sites throughout the cancer journey.
Mick Correll, Genospace.
“Genospace and Sarah Cannon share an unwavering commitment to serve people facing cancer by developing innovative approaches to treating their disease to ultimately improve outcomes,” says Mick Correll, CEO at Genospace. “Bringing together the expertise of Sarah Cannon’s physicians coupled with our leadership in molecular data integration and interpretation, we can impact the lives of hundreds of thousands of patients. We look forward to this next chapter at Genospace and to the advancements that will be made through our collaborative efforts.”
Terms of the agreement were not disclosed. Sarah Cannon expects to complete the transaction in the first quarter of this year. For more information, visit Genospace or Sarah Cannon.
